DK2707017T3 - Lixisenatid og metformin til behandling af diabetes type 2 - Google Patents
Lixisenatid og metformin til behandling af diabetes type 2 Download PDFInfo
- Publication number
- DK2707017T3 DK2707017T3 DK12723132.2T DK12723132T DK2707017T3 DK 2707017 T3 DK2707017 T3 DK 2707017T3 DK 12723132 T DK12723132 T DK 12723132T DK 2707017 T3 DK2707017 T3 DK 2707017T3
- Authority
- DK
- Denmark
- Prior art keywords
- patients
- treatment
- lixisenatide
- placebo
- treated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (13)
1. Farmaceutisk kombination til anvendelse til reduktion af niveauet af plasmaglucagon hos diabetes type 2-patienter, hvilken kombination omfatter (a) desPro36Exendin-4(1-39)-Lys6-NH2 og/eller et farmaceutisk acceptabelt salt deraf, (b) metformin og/eller et farmaceutisk acceptabelt salt deraf og (c) et sulfonylurinstof, hvor personen, der skal behandles, har en 2 timers postprandial plasmaglucosekoncentration på mindst 14 mmol/1.
2. Farmaceutisk kombination til anvendelse ifølge krav 1, hvor personen, der skal behandles, er adipøs.
3. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, har et BMI (body mass index) på mindst 30 kg/m2.
4. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, er en voksen person.
5. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, er blevet diagnosticeret med diabetes mellitus type 2 mindst 1 år eller mindst 2 år før behandlingsstart.
6. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, har en HbAic-værdi på ca. 7 til ca. 10 %.
7. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, har en fastende plasmaglucosekoncentration på mindst 8 mmol/1.
8. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, har et glucose-udsving på mindst 2 mmol/1, mindst 3 mmol/1, mindst 4 mmol/1 eller mindst 5 mmol/1, hvor glucose-udsvinget er forskellen mellem plasmaglucosekoncentrationen 2 timer postprandialt og plasmaglucosekoncentrationen 30 minutter før et måltid.
9. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor personen, der skal behandles, er af orientalsk og/eller asiatisk race.
10. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor desPro36Exendin-4(1-39)-Lys6-NH2 og/eller det farmaceutisk acceptable salt deraf er fremstillet til parenteral administration.
11. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor desPro36Exendin-4 (1-39)-Lys6“NH2 og/eller det farmaceutisk acceptable salt deraf er fremstillet til administration i en daglig dosis, der er udvalgt fra intervallet fra 10 yg til 20 yg.
12. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor metformin og/eller det farmaceutisk acceptable salt deraf er fremstillet til oral administration.
13. Farmaceutisk kombination til anvendelse ifølge et hvilket som helst af ovennævnte krav, hvor sulfonylurinstoffet er fremstillet til oral administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166120 | 2011-05-13 | ||
| EP12163637 | 2012-04-10 | ||
| PCT/EP2012/058747 WO2012156298A1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2707017T3 true DK2707017T3 (da) | 2016-01-04 |
Family
ID=46148833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12723132.2T DK2707017T3 (da) | 2011-05-13 | 2012-05-11 | Lixisenatid og metformin til behandling af diabetes type 2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130065828A1 (da) |
| EP (1) | EP2707017B1 (da) |
| JP (2) | JP6442284B2 (da) |
| KR (1) | KR20140043755A (da) |
| CN (2) | CN107693782A (da) |
| AU (1) | AU2012257849B2 (da) |
| BR (1) | BR112013029062A2 (da) |
| CA (1) | CA2835259C (da) |
| CY (1) | CY1117250T1 (da) |
| DK (1) | DK2707017T3 (da) |
| ES (1) | ES2556466T3 (da) |
| HK (1) | HK1194307A1 (da) |
| HR (1) | HRP20151369T1 (da) |
| HU (1) | HUE028459T2 (da) |
| MX (1) | MX362527B (da) |
| PL (1) | PL2707017T3 (da) |
| PT (1) | PT2707017E (da) |
| RU (1) | RU2623023C2 (da) |
| SI (1) | SI2707017T1 (da) |
| WO (1) | WO2012156298A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3016451A1 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
| US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
| KR101915454B1 (ko) | 2009-11-13 | 2018-11-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
| SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CA2932875A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| LT3229828T (lt) | 2014-12-12 | 2023-06-12 | Sanofi-Aventis Deutschland Gmbh | Insulino glargino/liksisenatido fiksuoto santykio kompozicija |
| TWI706779B (zh) * | 2015-01-16 | 2020-10-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 小兒第２型糖尿病病患之治療 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP4450127A2 (en) * | 2018-07-23 | 2024-10-23 | Eli Lilly and Company | Method of using a gip/glp1 co-agonist for diabetes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| EP2248531A1 (en) * | 2004-08-03 | 2010-11-10 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| EP2057188B1 (en) * | 2006-08-17 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| CN117547538A (zh) * | 2009-02-13 | 2024-02-13 | 勃林格殷格翰国际有限公司 | 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| HUE026489T2 (en) | 2009-11-13 | 2016-06-28 | Sanofi Aventis Deutschland | Combination of lixisenatide and metformin to treat type 2 diabetes |
-
2012
- 2012-05-11 EP EP12723132.2A patent/EP2707017B1/en not_active Revoked
- 2012-05-11 SI SI201230377T patent/SI2707017T1/sl unknown
- 2012-05-11 ES ES12723132.2T patent/ES2556466T3/es active Active
- 2012-05-11 AU AU2012257849A patent/AU2012257849B2/en active Active
- 2012-05-11 KR KR1020137033310A patent/KR20140043755A/ko active Search and Examination
- 2012-05-11 CN CN201711058028.0A patent/CN107693782A/zh active Pending
- 2012-05-11 DK DK12723132.2T patent/DK2707017T3/da active
- 2012-05-11 CN CN201280034737.4A patent/CN103841988A/zh active Pending
- 2012-05-11 PL PL12723132T patent/PL2707017T3/pl unknown
- 2012-05-11 HU HUE12723132A patent/HUE028459T2/en unknown
- 2012-05-11 US US13/469,633 patent/US20130065828A1/en not_active Abandoned
- 2012-05-11 PT PT127231322T patent/PT2707017E/pt unknown
- 2012-05-11 MX MX2013013307A patent/MX362527B/es active IP Right Grant
- 2012-05-11 CA CA2835259A patent/CA2835259C/en active Active
- 2012-05-11 JP JP2014509752A patent/JP6442284B2/ja active Active
- 2012-05-11 BR BR112013029062A patent/BR112013029062A2/pt not_active Application Discontinuation
- 2012-05-11 WO PCT/EP2012/058747 patent/WO2012156298A1/en active Application Filing
- 2012-05-11 RU RU2013155474A patent/RU2623023C2/ru active
-
2014
- 2014-08-04 HK HK14107943.7A patent/HK1194307A1/xx not_active IP Right Cessation
-
2015
- 2015-12-11 HR HRP20151369TT patent/HRP20151369T1/hr unknown
- 2015-12-15 CY CY20151101144T patent/CY1117250T1/el unknown
-
2018
- 2018-07-20 JP JP2018136356A patent/JP6676108B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012156298A1 (en) | 2012-11-22 |
| RU2013155474A (ru) | 2015-06-20 |
| US20130065828A1 (en) | 2013-03-14 |
| EP2707017A1 (en) | 2014-03-19 |
| EP2707017B1 (en) | 2015-09-16 |
| CA2835259C (en) | 2020-01-07 |
| AU2012257849B2 (en) | 2017-03-30 |
| CN103841988A (zh) | 2014-06-04 |
| HK1194307A1 (en) | 2014-10-17 |
| PL2707017T3 (pl) | 2016-03-31 |
| CN107693782A (zh) | 2018-02-16 |
| CA2835259A1 (en) | 2012-11-22 |
| JP6676108B2 (ja) | 2020-04-08 |
| RU2623023C2 (ru) | 2017-06-21 |
| HRP20151369T1 (hr) | 2016-01-15 |
| JP2018184441A (ja) | 2018-11-22 |
| HUE028459T2 (en) | 2016-12-28 |
| BR112013029062A2 (pt) | 2016-11-29 |
| KR20140043755A (ko) | 2014-04-10 |
| ES2556466T3 (es) | 2016-01-18 |
| JP2014514356A (ja) | 2014-06-19 |
| JP6442284B2 (ja) | 2018-12-19 |
| PT2707017E (pt) | 2016-01-12 |
| SI2707017T1 (sl) | 2016-01-29 |
| MX2013013307A (es) | 2014-03-12 |
| MX362527B (es) | 2019-01-23 |
| CY1117250T1 (el) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2707017T3 (da) | Lixisenatid og metformin til behandling af diabetes type 2 | |
| US20220054594A1 (en) | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 | |
| CA2851690C (en) | Treatment protocol of diabetes type 2 | |
| DK2750699T3 (da) | Farmaceutisk kombination til anvendelse til glykæmisk kontrol hos diabetes-type 2-patienter | |
| DK3010530T3 (da) | Formulering med fast forhold mellem insulin glargin og lixisenatid | |
| AU2012257849A1 (en) | Lixisenatide and metformin for treatment of diabetes type 2 | |
| PT2707015T (pt) | Lixisenatida como terapia adicional para além da insulina basal na diabetes tipo 2 | |
| EP3268029B1 (en) | Treatment of type 2 diabetes mellitus patients | |
| TW201311271A (zh) | 用於第２型糖尿病病患中血糖控制之醫藥組合物 |